Aarti Pharmalabs Launches Drive for Shareholders to Claim Dividends

Aarti Pharmalabs Ltd. has launched a special campaign to help its shareholders claim any unpaid or unclaimed dividends. The drive runs from April 1, 2026, to July 9, 2026, and is part of the national 'Saksham Niveshak' initiative led by the Investor Education and Protection Fund Authority (IEPFA).

Dividend Claim Campaign Launched

The company is actively encouraging shareholders to identify and claim dividends that have not yet been paid out or collected. This focused effort aims to ensure shareholders receive all their entitled funds.

Importance of Claiming Dividends

This initiative is vital because it prevents unclaimed funds from being transferred to the Investor Education and Protection Fund (IEPF) after a statutory period. By facilitating these claims, Aarti Pharmalabs demonstrates its commitment to good corporate governance and supporting its investors. Shareholders are reminded that updating their Know Your Customer (KYC) details is crucial to receive their entitlements directly.

About the 'Saksham Niveshak' Initiative

The 'Saksham Niveshak' campaign is a government-led effort by the IEPFA designed to boost financial literacy and ensure investors receive their due amounts. Companies participating in this program are encouraged to help shareholders resolve issues related to unclaimed dividends and shares. Aarti Pharmalabs, a manufacturer of Active Pharmaceutical Ingredients (APIs) and intermediates, was demerged from Aarti Industries in 2022 and serves global regulated markets.

Action Required for Shareholders

Shareholders with unpaid or unclaimed dividends must act quickly to update their KYC details. This includes verifying and ensuring the accuracy of their PAN, bank account, contact information, and nomination details with the company's Registrar & Share Transfer Agent, MUFG Intime India Private Limited, or their Depository Participant. All updates must be completed before the July 9 deadline.

Other Company Developments

Beyond the dividend drive, Aarti Pharmalabs is navigating several other matters. The company recently received a procedural observation from the US FDA following a March 2026 inspection of its Tarapur facility, for which a corrective and preventive action (CAPA) plan is being submitted. Separately, the Gujarat Pollution Control Board (GPCB) directed the closure of the company's Vapi plant in January 2025 due to alleged pollution control violations. Additionally, Aarti Pharmalabs is involved in a patent infringement lawsuit in Delhi court concerning its Ruxolitinib product, though the company anticipates no significant financial impact from this litigation.

Industry Peers

Key competitors for Aarti Pharmalabs in the Indian API and pharmaceutical sector include Divi's Laboratories, Dr. Reddy's Laboratories, Sun Pharmaceutical Industries, and Cipla Ltd. While this shareholder campaign is driven by specific regulatory guidance, these peer companies also engage in regular investor communications and adhere to corporate governance standards.